News

This little-discussed pipeline program could prove to be a big success.

VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics (NasdaqGM:CRSP) is set to participate in several major healthcare investor conferences in June. Senior management is scheduled to appear on live webcasts, where they may share business updates or discuss clinical development progress. These events give investors a direct opportunity to hear management’s latest views on the company’s direction and priorities. CRISPR Therapeutics, trading at $56.18, comes into these conferences after a 52.0% return over the past year,...

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with massive upside for 2026. As CASGEVY reinforced confidence in the company’s long-term growth outlook, CRISPR Therapeutics AG (NASDAQ:CRSP) received fresh support from Wall Street. On May 13, 2026, Bernstein raised its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) […]

Are there significant gains ahead for one (or both) of these innovative biotechs?

Q1 results and earnings estimate revisions put CRISPR Therapeutics (CRSP) in focus CRISPR Therapeutics (CRSP) has moved back onto investors’ radar after reporting a Q1 2026 net loss of US$122.9 million, smaller than the prior year, alongside progress across its gene editing pipeline. Management pointed to expanded programs, multiple anticipated 2026 milestones and recent positive shifts in earnings estimates. These developments give investors fresh information to assess how the stock’s long...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Best ARK Stocks to Buy Right Now. On May 4, CRISPR Therapeutics AG (NASDAQ:CRSP) reported its first quarter 2026 results and advanced its pipeline and commercial launch. The company reported a net loss of $122.9 million for Q1 2026, lower than $136.0 million a year earlier. […]

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics (NasdaqGM:CRSP) is entering a second phase of its business as the CASGEVY commercial rollout gains momentum. The company reports new patient initiations for CASGEVY alongside progress on reimbursement, including an agreement in Germany. Upcoming pipeline data and potential pediatric label expansion are expected to be important for future market uptake of CASGEVY. For investors tracking gene editing, CRISPR Therapeutics sits at the center of one of the most closely...

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

The biotech's innovative platform could pay off.

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Before you decide whether CRISPR Therapeutics stock looks attractive at around US$52.38, it helps to ask a simple question: what are you actually paying for compared with what the business might be worth? Over the last week the stock return is 0.6%, over the last month it is 5.8%, and over the last year it is 58.0%, while the year-to-date return is a 2.6% decline and the three- and five-year returns are 17.4% and 49.4% declines respectively, which may catch the eye of both momentum fans and...

Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

The biotech's candidate may treat a great number of illnesses that have one thing in common.

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the...

CRISPR Therapeutics AG (CRSP) reached $50.71 at the closing of the latest trading day, reflecting a -2.59% change compared to its last close.

These stocks come with risk, but they also have some exciting long-term growth opportunities.

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $52.06, representing a +2.1% change from its previous close.